Enhancing the anti-tumor effect of melphalan by prior administration of L-amino acid oxidase with or without intermediate administration of anti-L-amino acid oxidase antibody
US5523084A · kind A · utility
Assignees
Inventors
Key dates
| Filing date | Sep 7, 1994 |
| Grant date | Jun 4, 1996 |
| Priority date | — |
| Expiry date | Sep 7, 2014 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K16/40
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
L-amino acid oxidase is utilized to reduce plasma level of large neutral amino acids to allow the opportunity of increased melphalan transport into tumors and melphalan is administered when the plasma level of L-amino acid oxidase is sufficiently low so the gain from increased transport outweighs the loss from L-amino acid oxidase-mediated metabolism of melphalan. Preferably anti L-amino acid oxidase antibody is administered intermediate the L-amino acid oxidase and melphalan administrations to deplete L-amino acid oxidase activity once the L-amino acid oxidase has caused the melphalan transport improving plasma level reduction of large neutral amino acids thereby to reduce or eliminate degrading of melphalan by L-amino acid oxidase.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.